Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800042 | 1.00 | EPHX2 (0.50) | EPHX2MDM2KMT2AFOLH1MDM4 | |
| SCHEMBL3724258 | 1.00 | EPHX2 (0.50) | EPHX2MDM2KMT2AFOLH1MDM4 | |
| SCHEMBL29401644 | 0.91 | KMT2A (0.55) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL29359997 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL178698 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL29528567 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL260631 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL29401258 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL178733 | 0.85 | KMT2A (0.66) | MDM2KMT2AFOLH1MDM4TP53 | |
| SCHEMBL29679153 | 0.84 | MDM2 (0.49) | MDM2KMT2AMDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |